Avirmax Inc

CymaBay Therapeutics, Inc., located in Hayward, California, is dedicated to advancing health equity and delivering transformative therapies through innovative research in virology, oncology, and inflammation. As a leader in HIV programs in the U.S., the company boasts a robust pipeline of 58 clinical programs targeting some of the world's most pressing health challenges. Committed to community impact, CymaBay emphasizes inclusivity and diversity within its workforce while fostering scientific innovation to ensure its medicines reach those in need. With a focus on sustainability and global health access, the organization seeks to build a healthier world for all individuals. Generated from the website

Exelixis is an integrated drug discovery and development company. The company utilizes cutting-edge genomic, molecular biology and combinatorial chemistry technologies to develop innovative therapies for significant human diseases. Its primary mission is to improve patient care by developing proprietary human therapeutics that target the complex molecular causes of disease. Exelixis has built a research and discovery platform. The Exelixis clinical development pipeline includes compounds in cancer and renal disease. The company s pre-clinical pipeline is comprised of six programs. The pre-clinical oncology programs consist of development candidates that focus on inhibiting kinases. In its pre-clinical metabolic disease programs, Exelixis has developed small molecules that modulate nuclear hormone receptors that implicate various metabolic and cardiovascular disorders. Corporate headquarters are in San Francisco. The research facility is in Portland, Ore.

Cytokinetics is a biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule drugs that specifically target the cytoskeleton. The company s focus on the cytoskeleton enables it to develop novel and potentially safer and more effective classes of drugs directed at treatments for cancer, cardiovascular disease and other diseases. The company has developed a cell biology driven approach and proprietary technologies to evaluate the function of many interacting proteins in the complex environment of the intact human cell. The approach has yielded novel small molecule drug candidates that are in clinical development and two novel small molecule potential drug candidates in development, one in cancer and the other for heart failure. Its most advanced drug candidate, ispinesib is the subject of a Phase II clinical trials program designed to evaluate its effectiveness in many different types of cancer. Cytokinetics is headquartered in South San Francisco.